Department of Pharmacology and Toxicology, Comprehensive Cancer Center, Center for AIDS Research, General Clinical Research Center, The University of Alabama at Birmingham, Birmingham, AL, 35294, United States.
Department of Pharmacology and Toxicology, Comprehensive Cancer Center, Center for AIDS Research, General Clinical Research Center, The University of Alabama at Birmingham, Birmingham, AL, 35294, United States.
Int J Biochem Cell Biol. 2019 May;110:122-129. doi: 10.1016/j.biocel.2019.03.004. Epub 2019 Mar 5.
Thymidine phosphorylase (TP; EC 2.4.2.4) catalyzes the reversible phosphorolysis of thymidine, deoxyuridine, and their analogues to their respective nucleobases and 2-deoxy-α-d-ribose-1-phosphate (dRib-1-P). TP is a key enzyme in the pyrimidine salvage pathways. Activity of the enzyme is crucial in angiogenesis, cancer chemotherapy, radiotherapy, and tumor imaging, Nevertheless, a complete set of kinetic parameters has never been reported for any human TP. This study describes the kinetic mechanism and regulation of native human hepatic TP. The liver is a main site of pyrimidine metabolism and contains high levels of TP. Initial velocity and product inhibition studies demonstrated that the basic mechanism of this enzyme is a sequential random bi-bi mechanism. Initial velocity studies showed an intersecting pattern, consistent with substrate-enzyme-co-substrate complex formation, and a binding pattern indicating that the binding of the substrate interferes with the binding of the co-substrate and vice versa. Estimated kinetic parameters were K = 284 ± 55, K = 5.8 ± 1.9, K = 244 ± 69, and K = 90 ± 33 μM. Thymine was a product activator, but becomes a substrate inhibitor at concentrations eight times higher than its K. dRib-1-P was a non-competitive product inhibitor of the forward reaction. It bounded better to the Enzyme●P complex than the free enzyme, but had better affinity to the free enzyme than the Enzyme●Thymidine complex. In the reverse reaction, dRib-1-P enhanced the binding of thymine. The enhancement of the thymine binding along with the fact that dRib-1-P was a non-competitive product inhibitor suggests the presence of another binding site for dRib-1-P on the enzyme.
胸苷磷酸化酶(TP;EC 2.4.2.4)催化胸苷、脱氧胸苷及其类似物的可逆磷酸解,生成相应的核苷碱和 2-脱氧-α-D-核糖-1-磷酸(dRib-1-P)。TP 是嘧啶补救途径中的关键酶。该酶的活性在血管生成、癌症化疗、放疗和肿瘤成像中至关重要。然而,从未有过针对任何人类 TP 的完整的动力学参数集的报道。本研究描述了天然人肝 TP 的动力学机制和调节。肝脏是嘧啶代谢的主要部位,含有高水平的 TP。初始速度和产物抑制研究表明,该酶的基本机制是顺序随机双分子机制。初始速度研究显示出相交模式,与底物-酶-辅酶三元复合物的形成一致,并且结合模式表明,底物的结合干扰辅酶的结合,反之亦然。估计的动力学参数为 K=284±55、K=5.8±1.9、K=244±69 和 K=90±33 μM。胸苷是产物激活剂,但在浓度比其 K 高八倍时成为底物抑制剂。dRib-1-P 是正向反应的非竞争性产物抑制剂。它与 Enzyme●P 复合物的结合优于游离酶,但与游离酶的亲和力优于与 Enzyme●胸苷复合物的亲和力。在反向反应中,dRib-1-P 增强了胸苷的结合。胸苷结合的增强以及 dRib-1-P 是非竞争性产物抑制剂的事实表明,酶上存在另一个 dRib-1-P 结合位点。